Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
GO:00331271 | Esophagus | ESCC | regulation of histone phosphorylation | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:00725841 | Esophagus | ESCC | caveolin-mediated endocytosis | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:00316633 | Esophagus | ESCC | lipopolysaccharide-mediated signaling pathway | 37/8552 | 60/18723 | 9.17e-03 | 3.19e-02 | 37 |
GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
GO:00512161 | Esophagus | ESCC | cartilage development | 103/8552 | 190/18723 | 1.08e-02 | 3.67e-02 | 103 |
GO:00350512 | Esophagus | ESCC | cardiocyte differentiation | 86/8552 | 156/18723 | 1.09e-02 | 3.68e-02 | 86 |
GO:000989612 | Liver | Cirrhotic | positive regulation of catabolic process | 215/4634 | 492/18723 | 1.13e-20 | 3.56e-18 | 215 |
GO:003133112 | Liver | Cirrhotic | positive regulation of cellular catabolic process | 190/4634 | 427/18723 | 1.94e-19 | 4.18e-17 | 190 |
GO:000697912 | Liver | Cirrhotic | response to oxidative stress | 196/4634 | 446/18723 | 2.80e-19 | 5.86e-17 | 196 |
GO:000641712 | Liver | Cirrhotic | regulation of translation | 194/4634 | 468/18723 | 7.28e-16 | 8.79e-14 | 194 |
GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
GO:003238611 | Liver | Cirrhotic | regulation of intracellular transport | 147/4634 | 337/18723 | 1.84e-14 | 1.72e-12 | 147 |
GO:006219712 | Liver | Cirrhotic | cellular response to chemical stress | 147/4634 | 337/18723 | 1.84e-14 | 1.72e-12 | 147 |
GO:001623611 | Liver | Cirrhotic | macroautophagy | 129/4634 | 291/18723 | 1.75e-13 | 1.41e-11 | 129 |
GO:003459912 | Liver | Cirrhotic | cellular response to oxidative stress | 127/4634 | 288/18723 | 4.29e-13 | 3.32e-11 | 127 |
GO:00457277 | Liver | Cirrhotic | positive regulation of translation | 71/4634 | 136/18723 | 4.99e-12 | 3.52e-10 | 71 |
GO:005109812 | Liver | Cirrhotic | regulation of binding | 148/4634 | 363/18723 | 9.14e-12 | 5.97e-10 | 148 |
GO:001050611 | Liver | Cirrhotic | regulation of autophagy | 132/4634 | 317/18723 | 2.17e-11 | 1.33e-09 | 132 |
GO:001003812 | Liver | Cirrhotic | response to metal ion | 150/4634 | 373/18723 | 2.27e-11 | 1.37e-09 | 150 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa04520 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa04723 | Colorectum | AD | Retrograde endocannabinoid signaling | 59/2092 | 148/8465 | 2.94e-05 | 2.73e-04 | 1.74e-04 | 59 |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK3 | SNV | Missense_Mutation | | c.454C>T | p.Arg152Trp | p.R152W | P27361 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.908_909insACTTTGGGAGGCCGAGGTGGGTG | p.Asp305TrpfsTer15 | p.D305Wfs*15 | P27361 | protein_coding | | | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.1074_1075insGCTGTGGTGGGAGGACTGCTTGAACCTGGGAGAG | p.Arg359AlafsTer85 | p.R359Afs*85 | P27361 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.504_505insGAGGGGCTGCCCACTCCTGAAAGGAACGGAC | p.Pro169GlufsTer23 | p.P169Efs*23 | P27361 | protein_coding | | | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
MAPK3 | SNV | Missense_Mutation | rs774690695 | c.311G>A | p.Arg104Gln | p.R104Q | P27361 | protein_coding | tolerated(0.33) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK3 | SNV | Missense_Mutation | novel | c.819N>G | p.Ile273Met | p.I273M | P27361 | protein_coding | tolerated(0.11) | possibly_damaging(0.815) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK3 | SNV | Missense_Mutation | | c.869N>C | p.Val290Ala | p.V290A | P27361 | protein_coding | tolerated(0.24) | benign(0.075) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
MAPK3 | SNV | Missense_Mutation | | c.173N>T | p.Ser58Leu | p.S58L | P27361 | protein_coding | deleterious(0.01) | possibly_damaging(0.78) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
MAPK3 | SNV | Missense_Mutation | | c.251G>A | p.Arg84His | p.R84H | P27361 | protein_coding | deleterious(0.03) | probably_damaging(0.963) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MAPK3 | SNV | Missense_Mutation | rs764219989 | c.631N>T | p.Arg211Trp | p.R211W | P27361 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | (+)-ISOBICYCLOGERMACRENAL | CHEMBL2333548 | |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | ETOPOSIDE | ETOPOSIDE | 23999041 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | YUANHUADINE | YUANHUADINE | 21916433 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | CIMIRACEMATE A | CIMIRACEMATE A | 19835377 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | SELENIUM | | 14744887 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | NSC-753574 | CHEMBL2088730 | 22982122 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | PD-153035 | CHEMBL29197 | 17681471 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | MADOLIN A | MADOLIN A | |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | VOLVALERENAL D | VOLVALERENAL D | |